A trial of one KRAS G12D inhibitor is halted early, while that of another sees tox troubles.
ApexOnco Front Page
Recent articles
The group’s first pivotal readout, in second-line pancreatic cancer, is coming.
A deal with Jacobio is worth $100m up front.
Nenocorilant features among the latest industry projects newly into phase 1.
Two new PD-(L)1 x VEGF projects have entered the clinic.
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
The private ADC company is being wound down.
The new phase 3 trial, in first-line CLL, is expected to begin in January 2026.
